Stryker (NYSE:SYK) Coverage Initiated at Rothschild & Co Redburn

Key Points

• Rothschild & Co Redburn has initiated coverage on Stryker (NYSE:SYK) with a "neutral" rating and a price target of $420.00, indicating an 11.53% potential upside from its previous close.
• Analysts have given Stryker an average rating of "Moderate Buy" with a target price of $430.85, with fourteen analysts rating it a buy and five a hold.
• Stryker reported earnings of $3.13 per share, exceeding expectations and showing an 11.1% year-over-year revenue increase to $6.02 billion for the last quarter.

Analysts at Rothschild & Co Redburn started coverage on shares of Stryker (NYSE:SYK - Get Free Report) in a research note issued on Thursday,Briefing.com Automated Import reports. The firm set a "neutral" rating and a $420.00 price target on the medical technology company's stock. Rothschild & Co Redburn's price target points to a potential upside of 11.53% from the company's previous close.

Other equities research analysts have also recently issued research reports about the company. Needham & Company LLC boosted their price objective on Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Citigroup reiterated a "buy" rating and issued a $455.00 price target (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. BTIG Research reiterated a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Truist Financial set a $415.00 price target on shares of Stryker and gave the company a "hold" rating in a research report on Monday, August 4th. Finally, Wells Fargo & Company lifted their price target on shares of Stryker from $435.00 to $445.00 and gave the company an "overweight" rating in a research report on Friday, August 1st. Fourteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $430.85.

Stryker Stock Performance

SYK opened at $376.60 on Thursday. The business's 50-day moving average price is $388.10 and its two-hundred day moving average price is $379.40. Stryker has a 1 year low of $329.16 and a 1 year high of $406.19. The company has a market capitalization of $143.98 billion, a price-to-earnings ratio of 49.88, a P/E/G ratio of 2.71 and a beta of 0.93. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker's quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities analysts expect that Stryker will post 13.47 EPS for the current fiscal year.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Viju Menon sold 500 shares of the stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares of the company's stock, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of SYK. Mogy Joel R Investment Counsel Inc. raised its position in shares of Stryker by 3.4% during the 1st quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock valued at $36,561,000 after buying an additional 3,218 shares in the last quarter. Ferguson Wellman Capital Management Inc. boosted its stake in shares of Stryker by 1.9% during the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock valued at $65,096,000 after purchasing an additional 3,341 shares in the last quarter. Harbor Capital Advisors Inc. bought a new stake in Stryker during the first quarter worth about $1,840,000. Mar Vista Investment Partners LLC boosted its stake in Stryker by 10.2% during the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company's stock worth $33,572,000 after acquiring an additional 8,353 shares in the last quarter. Finally, United Services Automobile Association purchased a new position in Stryker in the first quarter worth about $2,857,000. 77.09% of the stock is owned by institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.